These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1650335)

  • 21. BRL 43694.
    Cancer Invest; 1989; 7(5):535. PubMed ID: 2559785
    [No Abstract]   [Full Text] [Related]  

  • 22. Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study.
    Moreno J; Sahade M; del Giglio A
    Support Care Cancer; 2005 Oct; 13(10):850-3. PubMed ID: 15838618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis.
    Cupissol DR; Serrou B; Caubel M
    Eur J Cancer; 1990; 26 Suppl 1():S23-7. PubMed ID: 2169782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of experience with ondansetron and granisetron.
    Aapro MS
    Ann Oncol; 1993; 4 Suppl 3():9-14. PubMed ID: 8395875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome.
    Prior A; Read NW
    Aliment Pharmacol Ther; 1993 Apr; 7(2):175-80. PubMed ID: 8387353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Method for individualized evaluation of antiemetic effect induced by 5-HT3 receptor antagonist.
    Nakamura H; Yokoyama H; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
    Biol Pharm Bull; 2013; 36(5):780-7. PubMed ID: 23459393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockade of 5-HT3 receptors with granisetron does not affect trigeminothalamic nociceptive transmission in rats: Implication for migraine.
    Sokolov AY; Sivachenko IB; Panteleev SS; Lyubashina OA
    Clin Exp Pharmacol Physiol; 2018 Jan; 45(1):34-41. PubMed ID: 28853174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of efficacy of the 5-HT3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia.
    Poyurovsky M; Weizman A
    Int Clin Psychopharmacol; 1999 Nov; 14(6):357-60. PubMed ID: 10565803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.
    Bermudez J; Boyle EA; Miner WD; Sanger GJ
    Br J Cancer; 1988 Nov; 58(5):644-50. PubMed ID: 2851311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
    Chevallier B
    Eur J Cancer; 1990; 26 Suppl 1():S33-6. PubMed ID: 2169784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of 1 mg/body and 3 mg/body of intravenous granisetron for the prevention of chemotherapy-induced nausea and vomiting and adverse events in hematological malignancy patients].
    Motohashi S; Hori K; Ono T; Ohnishi K; Kawakami J
    Yakugaku Zasshi; 2012; 132(5):675-81. PubMed ID: 22687700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-HT3 receptor antagonists and migraine therapy.
    Ferrari MD
    J Neurol; 1991; 238 Suppl 1():S53-6. PubMed ID: 2045832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron).
    Sanger GJ; Nelson DR
    Eur J Pharmacol; 1989 Jan; 159(2):113-24. PubMed ID: 2540014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
    Ishioka S; Sagae S; Saito T; Kiya T; Sugimura M; Akutagawa N; Umemura K; Ito E; Kudo R
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):593-8. PubMed ID: 10791002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
    Jones AL; Lee GJ; Bosanquet N
    Eur J Cancer; 1992; 29A(1):51-6. PubMed ID: 1332738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Physiopathology of migraine].
    Goadsby PJ; Lance JW
    Rev Prat; 1990 Feb; 40(5):389-93. PubMed ID: 1968676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy.
    Tabona MV
    Eur J Cancer; 1990; 26 Suppl 1():S37-44. PubMed ID: 2169785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694).
    Reynolds DJ; Barber NA; Grahame-Smith DG; Leslie RA
    Brain Res; 1991 Nov; 565(2):231-6. PubMed ID: 1668810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.